ABCAM Plc
07 May 2008


For immediate release                                               7 May 2008



                                  ABCAM PLC
                           ("Abcam" or "the Company")


                          Grant of Share Options to Director

Cambridge UK, 7 May 2008: Abcam plc announces that on 7 May 2008, Jonathan
Milner, Chief Executive of the Company, was granted options as detailed below
over Ordinary Shares of 1p each in the Company, at an exercise price of 413p per
share.

The Abcam 2005 Share Option Scheme - 41,162 Ordinary Shares

The Abcam Enterprise Management Incentive Scheme - 4,842 Ordinary Shares

Following this grant of options Dr Milner has a total of 99,019 options over
Ordinary Shares of 1p each in the Company under the Abcam 2005 Share Option
Scheme, and a total of 40,556 options over Ordinary Shares of 1p each in the
Company under the Abcam Enterprise Management Incentive Scheme.


For further information please contact:

Abcam                                                     + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities                                         + 44 (0) 20 7260 1000
James Black / Nick Westlake

Buchanan Communications                                  + 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson / Susanna Gale



Notes for editors:



About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a
Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades
under the ticker symbol ABC.  The Company produces and distributes its own and
third party produced antibodies to academic and commercial users throughout the
world with product information provided and ordering available through the
Company's website, www.abcam.com. The antibodies are sold under the Abcam brand
name. The Company's vision is to build the largest online antibody resource in
the world while also ensuring that the antibodies are of high quality and
commercially viable. Abcam now has an online catalogue of over 42,500 products,
most of which are antibodies, from over 200 suppliers supported by up-to-date
and detailed technical data sheets, which are created by the Company. The
Company currently employs 178 staff in its three operating companies.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

• News Channel